生命科学资讯

GLP-1s support heart attack recovery in rodents by relaxing tight blood vessels

Is Illumina’s (ILMN) TruPath Rare Disease Push Reframing Its Clinical Sequencing Investment Narrative? - simplywall.st

Lonza Group AG: Quiet Rally In Swiss Biotech That U.S. Investors Are Missing - AD HOC NEWS

Cardiogenetic testing at scale: the TruGenome Cardiovascular Disease Test and CardioSeq Clinical Trial - Illumina

Agilent Technologies Signals Steady Growth Amid Headwinds - TipRanks

Agilent's Stock Plummets 2.64% as Trading Volume Dips to $0.41B, Ranking 322 in Daily Trading Activity Amid Earnings Miss and Post-Earnings Rally - Bitget

HHS bans Claude AI tool as Trump seeks full government blacklisting of Anthropic

Morgan Stanley cuts Agilent stock price target on valuation multiples - Investing.com

Waters Corporation (WAT) Investor Outlook: Evaluating A Potential 24.63% Upside - DirectorsTalk Interviews

Thermo Fisher (NYSE: TMO) HR chief disposes shares to cover tax liability - Stock Titan

Major RSU grant to 10x Genomics (TXG) CEO Serge Saxonov - Stock Titan

Two more members added to ACIP ahead of March meeting

Breaking Down 10x Genomics: 11 Analysts Share Their Views - Benzinga

Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout

TCE biotech Candid scores Nasdaq listing via reverse merger with rare disease-focused Rallybio

Boehringer axes MASH deal with OSE as biotech continues to whittle down pipeline

Thermo Fisher Scientific: Recovery In Life Sciences Solutions (NYSE:TMO) - Seeking Alpha

Assessing Agilent Technologies (A) Valuation After Recent Share Price Softness and Long Term Gains - Yahoo Finance

Ascendis wins FDA approval of dwarfism drug

Illumina Inc (ILMN) Trading Down 2.84% on Mar 2 - GuruFocus